AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00522587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed sevoflurane dose 4
Description: Dose 4 of sevoflurane
Study NCT00522587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed sevoflurane dose 5
Description: Dose 5 of sevoflurane
Study NCT00522587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed sevoflurane dose 6
Description: Dose 6 of sevoflurane
Study NCT00522587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed remifentanil dose 1
Description: Dose 1 of remifentanil
Study NCT00522587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed remifentanil dose 2
Description: Dose 2 of remifentanil
Study NCT00522587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed remifentanil dose 3
Description: Dose 3 of remifentanil
Study NCT00522587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed remifentanil dose 4
Description: Dose 4 of remifentanil
Study NCT00522587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed remifentanil dose 5
Description: Dose 5 of remifentanil
Study NCT00522587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed remifentanil dose 6
Description: Dose 6 of remifentanil
Study NCT01479543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic CNCM I-4034
Description: Probiotic CNCM I-4034 in a concentration of 9x10E9 cfu (colony forming unit) per day during 28 days.
Study NCT01479543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic CNCM I-4035
Description: 9x10E9 cfu (colony forming unit) per day during 28 days.
Study NCT01479543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic CNCM I-4036
Description: 9x10E9 cfu (colony forming unit) per day during 28 days.
Study NCT01479543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotics CNCM I-4035 and CNCM I-4036
Description: 9x10E9 cfu (colony forming unit) per day during 28 days.
Study NCT01479543 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule for 28 days.
Study NCT01957358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Grief Recovery Method
Description: The Grief Recovery Method is a structured process designed to help people with spinal cord injuries examine their knowledge of their injury, their emotional reaction to their injury, and their ability to acknowledge their grief over the injury in order to learn techniques to resolve the grief in order to achieve a more complete recovery. Participants will attend a total of 18 sessions, some one-on-one, and some in a group setting. The Grief Recovery Handbook, handouts, DVD (digital video disc) presentations and questionnaires will be used. Targeted activities to decrease isolation and assist volunteers to identify goals for recovery will be utilized.
Study NCT01109784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel
Description: prasugrel 10 mg/day
Study NCT01109784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: clopidogrel per os 150mg/day
Study NCT03099889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Physical activity intervention based upon stage of change and social cognitive theory based interventions
Study NCT02230280 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Strengthening Community-Based Stroke Care: A Pilot Study of a Community Navigation and Rehabilitation Intervention that Includes a Mobile Health Solution
Description: Participants will be offered regular in-home visits over the 6-month study period in addition to usual outpatient rehabilitation services. The health care providers will have access to a mobile health application (MYST) to share real-time information and access community resources and best practice guidelines.
Study NCT02936700 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Relaxation
Description: relaxation program consists of 7 weekly, 2 hours sessions led by two therapist. Each group will consist of 7 participants.
Study NCT02936700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT therapy
Description: 7 weekly, 2 hours sessions led by two therapist. Each group will consist of 7 participants. The ACT program aims at~* decreasing the tendency to try to escape unpleasant mental experiences~* increasing psychological flexibility~* developing acceptance of psychological events and engagement in valued actions
Study NCT04338958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 2 x 10mg Ruxolitinib with defined response adapted dose escalation up to 2 x 20mg for a duration of 7 days with clinical and/or radiographic response assessment
Study NCT03361397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: Lidocaine hydrochloride will be used via mask nebulizer before LMA insertion
Study NCT03361397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Distilled Water
Description: Distilled Water will be used via mask nebulizer before LMA insertion
Study NCT01888042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg (1 tablet of 10 mg)
Study NCT01127724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin B12 treatment
Description: Group I- will receive sublingual vitamin B12 treatment, 1000 mcg per day for 6 months Group II- will receive sublingual vitamin B12 treatment, 100 mcg per day for 6 months Group III- will receive sublingual vitamin B12 treatment, 2000 mcg per day for 6 months
Study NCT04029519 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PN40082
Description: PN40082 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.
Study NCT04253275 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: blood samples
Description: Blood samples will be taken at inclusion, 12h, 24h, 48h, 7d, 3m and 1y for patients ; at inclusion, 3m and 1y for controls.~Microvesicles samples will be taken at inclusion, 7d and 3M ; at inclusion and 3M for controls.
Study NCT04253275 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI without injection
Description: MRI at inclusion for controls
Study NCT03643380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AHLeveeS System
Description: AHLeveeS System for treatment of overactive bladder
Study NCT04251637 — intervention group
Intervention type: OTHER
Intervention: Cardiac output monitoring with Starling SV.
Description: Intraoperative monitoring of cardiac output by esophageal Doppler, NICOM Starling SV and collection of values for each patient at at least 7 predefined intraoperative times.
Study NCT02841215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin 200 µg/kg
Description: Oral ivermectin 200 µg/kg three times (D0, D7 and D14) + topical treatment (permethrin 5% cream) on skin, hair and genital organs (D0 and D7) + emollient cream (Dexeryl® or other) daily on skin (D0 to D28)
Study NCT02841215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin 400 µg/kg
Description: Oral ivermectin 400 µg/kg three times (D0, D7 and D14) + topical treatment (permethrin 5% cream) on skin, hair and genital organs (D0 and D7) + emollient cream (Dexeryl® or other)daily on skin (D0 to D28)
Study NCT02585505 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stem cells
Description: stem cell will be injected
Study NCT03828929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: IV vitamin C, 1500mg in 50ml of normal saline every six hours, infused over one hour and IV Thiamine 200mg in 50ml of 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
Study NCT03828929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 50ml of IV normal saline every six hours and 50ml of IV 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
Study NCT01514227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin or thienopyridine
Description: Subjects randomized 6 month DAPT will be prescribed either aspirin or thienopyridine (clopidogrel or ticlopidine) following 6 months DAPT for the duration of study, which is left on the physician's discretion.
Study NCT01514227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin and thienopyridine
Description: Subjects randomized 18 month DAPT will be prescribed both aspirin and thienopyridine (clopidogrel or ticlopidine) for 18 month after stenting.
Study NCT00907101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)
Description: Apply once daily
Study NCT00313209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: 500 µg, once daily, oral administration in the morning
Study NCT00313209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily
Study NCT03572127 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: High protein diet derived from either animal or non-animal sources.
Study NCT03572127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: High protein diet derived from either animal or non-animal sources.
Study NCT02018627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeris glucagon
Description: The subject is given an injection of xeris glucagon
Study NCT02018627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lilly glucagon
Description: The subject is given an injection of lilly glucagon
Study NCT04538794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-0159
Description: Administered intravenously
Study NCT04538794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Administered intravenously
Study NCT03344302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: intravenous infusion of oxytocin 30 units over 5 minutes diluted into 500 mL of normal 0.9% sodium chloride
Study NCT03344302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intravenous infusion of oxytocin 30 units over 5 minutes diluted into 500 mL of normal 0.9% sodium chloride
Study NCT02436876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBN-101
Description: MBN-101 is a locally administered, anti-infective drug product
Study NCT02436876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo is comprised of the vehicle/excipients used to formulate MBN-101, but does not contain the active pharmaceutical ingredient
Study NCT03901950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW7201 tablets
Description: A wnt pathway inhibitor
Study NCT03017170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dried Cranberry
Description: Dried cranberry powder is not an extract of cranberries, but a full spectrum ingredient. It is comprised of a proprietary ratio of dried cranberry fruit, cranberry pomace, and cranberry seeds, each of which is a recognized food and/or dietary ingredient. One 500 mg capsule of dried cranberry powder consists of approximately 25 grams of cranberry fruit.
Study NCT03017170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Colored Maltodextrin: Proprietary mixture of: maltodextrin and food grade colors
Study NCT00193895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will commence with a dose calculated to target an AUC of 2.0. A maximum of 6 doses of weekly Carboplatin will be given. Carboplatin will be administered intravenously over 20-30 minutes prior to radiation therapy.
Study NCT00193895 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 60 Gy OR 66Gy in 2Gy/fraction 5days/week
Study NCT00193895 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 60 Gy OR 66Gy in 2Gy/fraction 5days/week
Study NCT01297335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine
Description: Intrathecal Clonidine
Study NCT02931721 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Pelvis MRI
Study NCT01899235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug eluting balloon
Study NCT01899235 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drug eluting stent
Study NCT03436862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg IV infusion over 60 minutes given every 2 weeks for up to 6 months.
Study NCT02961335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done
Study NCT02961335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Confocal microendoscopy
Description: Confocal microendoscopy will be performed during this initial bronchoscopy
Study NCT02961335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy sampling
Description: Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done
Study NCT02609360 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Priming of ECMO circuit with 0.9% NaCl
Description: 0.9% NaCl as priming crystalloid solution
Study NCT02609360 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Priming of ECMO circuit with Ringer Lactate
Description: Ringer Lactate as priming crystalloid solution
Study NCT02609360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Priming of ECMO circuit with Balanced Solution
Description: Balanced Solution as priming crystalloid solution
Study NCT03333031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-196
Description: HS-196 will be administered intravenously as a single dose
Study NCT00110773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)
Description: S-Caine Peel, composed of a 1:1 (w:w) eutectic mixture of 7% lidocaine and 7% tetracaine, applied topically. S-Caine Peel applied at approximately 1 mm in thickness and remained on the treatment area for 20 minutes (±2 minutes).
Study NCT00110773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Peel
Description: Placebo Peel applied topically at approximately 1 mm in thickness and remained on the treatment area for 20 minutes (±2 minutes).
Study NCT01789450 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Section of Periareolar Dermis in Breast Reduction.
Study NCT02229552 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standardized Assessments
Description: Children were asked to attend appointments without consuming study foods 24 hours previously, as habituation measurements are sensitive to recent consumption. Children were provided access to snack prior to completing questionnaires or cognitive assessments. Habituation to food, questionnaires and cognitive assessments were re-measured at 1-year and 2-year follow up.
Study NCT04388995 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: volume expansion
Description: volume expansion with 6% hydroxyethyl starch (7 mL/kg) at a rate of 0.4 mL/kg/min
Study NCT01692301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: 200 mg tablet
Study NCT01692301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan
Description: 20 mg and 40 mg capsules
Study NCT01692301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696 matching placebo
Description: LCZ696 Matching Placebo tablet
Study NCT01692301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LCZ696 matching placebo
Description: LCZ696 Matching Placebo tablet
Study NCT01692301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan matching placebo
Description: Olmesartan matching placebo capsule
Study NCT01692301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine
Description: amlodipine 2.5 mg or 5 mg tablets
Study NCT01692301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine
Description: amlodipine 2.5 mg or 5 mg tablets
Study NCT01692301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide
Description: hydrochlorothiazide 6.25mg, 12.5mg, or 25 mg tablets
Study NCT01692301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrochlorothiazide
Description: hydrochlorothiazide 6.25mg, 12.5mg, or 25 mg tablets
Study NCT00467454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: daily
Study NCT00467454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily
Study NCT04580381 — intervention group
Intervention type: DRUG
Intervention: Natalizumab Injection [Tysabri]
Description: Natalizumab infusion interval according to local practice defining the patient's group
Study NCT03604965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP+CCRT
Description: Patients receive Neoadjuvant gemcitabine (1000mg/m2 on day1 and day8 ) and cisplatin (80mg/m2 on day1)every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 or day2)every 21 days for three cycles during radiotherapy
Study NCT03604965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPF+CCRT
Description: Patients receive Neoadjuvant Docetaxel (75mg/m2 on day1 03:30-04:30) and cisplatin (75mg/m2 on day 1-5 10:00-22:00) and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 or day2)every 21 days for three cycles during radiotherapy
Study NCT00566930 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: spinal manipulation
Description: Monthly cervical spinal manipulation
Study NCT00566930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal manipulation + exercises
Description: Monthly cervical spine manipulation and daily home exercises
Study NCT04360902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anemia Controller
Description: Model Predictive Controller software (called Anemia Controller) that utilizes our physiology-based erythropoiesis model to provide ESA dosing recommendations in order to guide a patient's Hgb level towards a predefined target value.
Study NCT04515732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Oral Tablet
Description: As in description
Study NCT02905565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NBP Softgel Capsules
Description: Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing.
Study NCT02905565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing
Study NCT02767648 — intervention group
Intervention type: OTHER
Intervention: proteomic urine analysis
Description: proteomic urine analysis
Study NCT02762474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel group
Description: Weekly Regimens of Nab-paclitaxel Plus Cispaltin Combined With Concurrent IMRT
Study NCT03664414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pentoxifylline
Description: Pentoxifylline or placebo will be prescribed three times a day with meals. All the participants will continue with the usual treatment. Time frame: two years
Study NCT03664414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pentoxifylline
Description: Pentoxifylline or placebo will be prescribed three times a day with meals. All the participants will continue with the usual treatment. Time frame: two years
Study NCT03987854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet and lifestyle program
Description: Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep. They will also be taught taught about positive affect skills (such as gratitude, positive reappraisal, and personal strengths) and mindfulness (general mindfulness and mindful eating).
Study NCT02138032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gains Framed Message
Study NCT02138032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss Framed Message
Study NCT04577443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: To investigate the role of adenosine on cerebral hemodynamic and headache in healthy volunteers and migraine patients
Study NCT04577443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: To investigate the role of saline on cerebral hemodynamic and headache in healthy volunteers and migraine patients
Study NCT04659460 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning
Description: RIC interventions will be applied to the upper extremity calibrated to induce four, ten-minute cycles of five-minutes-ischemia and five-minutes-perfusion for a total of 20 cumulative minutes of limb ischemia, at a pressure of 250 mmHg.